Baessler, Andrea and Fischer, Marcus (2022) Novel options to maximize oral lipid lowering treatment Role of bempedoic acid in combination treatment. HERZ, 47 (3). pp. 212-219. ISSN 0340-9937, 1615-6692
Full text not available from this repository. (Request a copy)Abstract
Epidemiological, randomized, controlled, clinical and genetic studies confirm that low-density lipoprotein cholesterol (LDL-C) is a causative factor for atherosclerotic diseases. The current European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) guidelines on the management of dyslipidemia recommend a target LDL-C < 55 mg/dl and at least a 50% reduction in baseline LDL-C for high-risk patients; however, these target values are often not achieved in routine clinical practice, as shown by recent cross-sectional data from EUROASPIRE or DaVinci. Therefore, combination treatment is recommended, which, as with treatment of blood pressure, can improve the success of treatment. Bempedoic acid is a new substance, which is suitable for combination treatment and represents an alternative particularly for patients with statin-associated muscular symptoms. Bempedoic acid reduces LDL-C by approximately 25% in statin-naive patients and by some 18% in addition to statins. In a fixed doses combination with ezetimibe, bempedoic acid can lower LDL-C by up to 45% in statin-naive patients and by 38% (placebo-corrected) in addition to statins. Bempedoic acid is generally very well tolerated: however, it can lead to a reversible increase in uric acid. Occasionally, a slight decrease in hemoglobin has been documented. Therefore, it is recommended that not only changes in lipid levels but also uric acid and hematological parameters should be monitored in the first 3 months.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-HEART-DISEASE; LDL-CHOLESTEROL; BLOOD-PRESSURE; MENDELIAN RANDOMIZATION; CARDIOVASCULAR-DISEASE; METAANALYSIS; EFFICACY; THERAPY; SAFETY; LDL cholesterol; Dyslipidemia; Hypercholesterolemia; Cardiovascular risk; Statin intolerance |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin II |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 14 Feb 2024 10:07 |
| Last Modified: | 14 Feb 2024 10:07 |
| URI: | https://pred.uni-regensburg.de/id/eprint/57364 |
Actions (login required)
 |
View Item |
